Brookline Capital Management Estimates Genelux Q1 Earnings

Genelux Corporation (NASDAQ:GNLX) – Investment analysts at Brookline Capital Management issued their Q1 2026 earnings per share estimates for shares of Genelux in a note issued to investors on Thursday, November 6th. Brookline Capital Management analyst K. Dolliver anticipates that the company will post earnings of ($0.20) per share for the quarter. The consensus estimate for Genelux’s current full-year earnings is ($0.88) per share. Brookline Capital Management also issued estimates for Genelux’s Q2 2026 earnings at ($0.20) EPS, Q3 2026 earnings at ($0.21) EPS and Q4 2026 earnings at ($0.21) EPS.

Genelux (NASDAQ:GNLX) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.02.

Several other analysts also recently commented on GNLX. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Genelux in a report on Wednesday, October 8th. HC Wainwright reaffirmed a “buy” rating on shares of Genelux in a report on Wednesday, July 23rd. Maxim Group set a $20.00 price objective on Genelux in a research note on Tuesday, October 21st. Lake Street Capital started coverage on Genelux in a research note on Tuesday, October 21st. They issued a “buy” rating and a $16.00 target price on the stock. Finally, Loop Capital set a $16.00 target price on Genelux in a report on Tuesday, October 21st. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $21.00.

Genelux Trading Up 2.3%

Shares of NASDAQ:GNLX opened at $5.42 on Monday. Genelux has a twelve month low of $1.99 and a twelve month high of $8.53. The company has a market cap of $206.23 million, a PE ratio of -6.16 and a beta of -0.10. The company’s 50 day moving average is $5.18 and its 200 day moving average is $3.78.

Hedge Funds Weigh In On Genelux

Several institutional investors and hedge funds have recently modified their holdings of the business. Private Management Group Inc. purchased a new position in Genelux during the second quarter worth approximately $33,000. Liberty Wealth Management LLC acquired a new position in shares of Genelux during the 1st quarter worth approximately $45,000. American Century Companies Inc. purchased a new position in shares of Genelux during the 1st quarter valued at approximately $51,000. Beacon Capital Management LLC grew its stake in Genelux by 99.8% in the 2nd quarter. Beacon Capital Management LLC now owns 19,116 shares of the company’s stock valued at $55,000 after acquiring an additional 9,550 shares during the period. Finally, Falcon Wealth Planning raised its position in Genelux by 83.3% during the second quarter. Falcon Wealth Planning now owns 22,000 shares of the company’s stock worth $63,000 after acquiring an additional 10,000 shares during the period. Hedge funds and other institutional investors own 37.33% of the company’s stock.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.